title: Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer.
abstract: OBJECTIVE
  We investigated the significance of pre-treatment screening by (18)F-fluorodeoxyglucose positron-emission tomography (FDG-PET) in patients with esophageal cancer.
  
  
  METHODS
  We retrospectively evaluated the clinical significance of screening in 200 patients with primary esophageal cancer using FDG-PET.
  
  
  RESULTS
  Out of 200 patients, 34 (17%) had synchronous multiple primary tumors; 31 patients had two types of cancers (15.5%) and three patients had three types (1.5%). The 37 second and third primary tumors were 13 stomach cancers (35.1%), 13 head and neck cancers (35.1%), seven colon (18.9%) and two lung (5.4%) cancers. When PET was performed at initial treatment for esophageal cancer, the diagnostic sensitivity of FDG-PET/Computed tomography (CT) for the second and third synchronous primary cancer were 53.8% (7/13) for the stomach; head and neck, 61.5% (8/13); colon, 42.9% (3/7); and lung, 50% (1/2), for an overall sensitivity of 54.1% (20/37 sites).
  
  
  CONCLUSIONS
  FDG-PET/CT for patients with esophageal cancer may find both metastases from the primary esophageal cancer and other types of synchronous primary cancers.
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. tatsuyamiyazaki@gunma-u.ac.jp.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Makoto
authors.initials: M
authors.lastname: Sohda
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Higuchi
authors.forename: Naritaka
authors.initials: N
authors.lastname: Tanaka
authors.forename: Shigemasa
authors.initials: S
authors.lastname: Suzuki
authors.forename: Makoto
authors.initials: M
authors.lastname: Sakai
authors.forename: Takehiko
authors.initials: T
authors.lastname: Yokobori
authors.forename: Masanobu
authors.initials: M
authors.lastname: Nakajima
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tsushima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuwano
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Double cancer; FDG-PET; esophageal cancer; multiple primary neoplasm; triple cancer